高剂量与常规剂量表阿霉素治疗NSCLC疗效比较
The Response Rate of High Dose Epirubicin in Comparison with Conventional Dose on NSCLC
-
摘要: 目的:比较高剂量与常规剂量表阿霉素联合化疗方案治疗非小细胞肺癌(NSCLC)的疗效,并观察两组的毒性反应。方法:30例ⅡⅣ期非小细胞肺癌随机分成两组,每组15个病人,一组为高剂量表阿霉素组(EPI:100mg/M2),一组为常规剂量表阿霉素组(EPI:75mg/M2)。两组均采用MEP方案(MMC+EPI+DDP)治疗2周期。结果:显示高剂量、常规剂量表阿霉素组有效率(RR)分别为40.0%和20.0%。从有效率来看高剂量表阿霉素组(HDEPI组)要高于常规剂量表阿霉素组(CDEPI组),虽然两组疗效无统计学上差异((P<0.05)。HDEPI组发生口腔粘膜炎较多,有统计学意义(P<0.05),而其它毒性如胃肠道反应、骨髓抑制、静脉炎、脱发两组无显著差别((P<0.05),所有病例均未见明显的心脏毒性。结论:从实际值看HDEPI组疗效优于CDEPI且,而主要毒性反应两组无显著差异,值得临床推广和深入研究。Abstract: Objective: Our objective is to evaluate the efficacy of high close epirubicin combination chemtherapy in comparison with conventional dose in the treatment of non-small cell lung cancer (NSCLC) and to observe the toxicity between the two groups. Methods:30 patients with NSCLC (stage II一IV) were randomized into two groups.Each group had 15 patients. One group was treated with high dose epirubicin (HD EPI: 100mg/M2).Another group was used with conventional dose epirubicin(CD EPI: 75mg/ MZ).A ll these 30 patient s were treated with MEP (mi tomycin C+ epirubicin+ cisplatin)regimen for 2 cycles. Results: The results showed that the response rates CRR) of high close and conventional dose epirubicin groups were of 40.0% and 20.0%，respectively. The RR of HD EPI was much higher than that of CD EPI, though there was no statistical difference between the two groupe (P> 0.05).The HD EPI group had more oral mucositis. The difference was statistically significant (P<0.05).However, there was no notable statistical difference(P>0. 05)between the two groups regarding other toxicity such as gastrointestinal tract reaction, myelosuppression, phlebitis and alopecia.Obvious cardiotoxicity was not found in all patients. Conclusion; The response rate of the HD EPI group is better than that of the CD EPI group acxeording to the actual value. There is no siginificant statisitical difference betweenn the two groups concerning the main toxicity .Thus, these results are worthwhile for dinicalextensive application and further study.
-
Key words:
- Epirubicin /
- Nori small cell lung cancer /
- Combination chemotherapy
-
-
[1] Weiss RB.The anthracyclines:Wil we ever find a better do xorubicin ? Semis Onceh 1992, 19(6):670 [2] Rosen HR,Minow RA,Leier CV,et al.Epirubicin and Doxorrubicin:A comparison of the characteristic therapeutic activity and toxicity.Cancer Treat Rev,1993,19(3):197 [3] 林震琼，徐昌文，等.小细胞肺癌化疗后的病理学观察--附48例分析.中华肿瘤杂志，1988, 6(10):452-454 [4] Martoni A,Melotti B, et al. High-dose epirubicin for untreated patients with advanced tumours a phase I study.Eur-J-Cancer,1990, 26(11-12):1137-1140 [5] Cersoimo RJ，et al.Epirubicin:a review of the pliarmacology,clinical activity,and adverse effects of anadriamvcin anabgue.,J-Clim-On-col, 1986,4:425-439 [6] Martoni A, et al.Activiy of high dose epimbicin in advanced non-small-cell lung Cancer. Eur-J-Cancer,1991, 27(10):1231-1234 [7] Martoiu A. Guaraldi M, et al.A phrase II study of high- dose epirubici plus cisplatinum in advanced non-small-cell lung cancer (NSCLC),Ann-oncol 1992, 12,3(10):864-866
计量
- 文章访问数: 1111
- HTML全文浏览量: 21
- PDF下载量: 347
下载:
